Darzalex (Daratumumab) a Promising New Immunotherapy for Multiple Myeloma Cancer

http://youtu.be/TQwqvujqDFU Darzalex (Daratumumab) is a promising new FDA approved immunotherapy for treating multiple myeloma cancer, which is currently the 3rd most commonly diagnosed blood cancer in the United States. In this video, oncologist Dr. Stephen Lemon talks about how Darzalex is used to treat multiple myeloma, including what types of side effects it may cause. Visit http://www.oacancer.com/darzalex-daratumumab-treats-multiple-myeloma-cancer/ to learn more on this drug. Darzalex is approved for the treatment of patients with multiple myeloma who have received at least 3 or more prior types of myeloma treatments. Multiple myeloma occurs when malignant plasma cells uncontrollably grow in the bone marrow, producing too much of a protein called CD38 which can result in cancerous tumor growth. Used as a targeted therapy, Darzalex searches for these malignant cells to destroy them. Darzalex is developed by Janssen Biotech. Dr. Stephen Lemon is a medical oncologist at Oncology Associates of Omaha, which is not affiliated with Janssen Biotech. These medical videos are produced to help give patients and their families a better understanding of newly approved cancer treatments. Visit http://www.oacancer.com to learn more about Oncology Associates and their approach to personalized cancer treatment.